论文部分内容阅读
目的 探讨拉米夫定对前 C基因变异的慢性乙型肝炎患者纤维化的作用。方法 慢性乙型肝炎患者且 HBe Ag阴性、 HBV DNA阳性、血清肝纤维化指标 4项中有 2项或 2项以上超过正常值 39例 ,随机分为拉米夫定组 2 6例和对照组13例 ,治疗前后检测 HBV DNA、 TB、 AL T、 A / G和肝纤维化血清学指标 HA、 L N、 PC 、 C 。结果 拉米夫定组 2 6例中有 2 3例 HBV DNA转阴 ,转阴率为 88.46 % ,TB、AL T有显著下降 ,A/ G有明显上升。两组比较有显著性差异 (P <0 .0 1。肝纤维化指标均有明显下降 ,两组比较有显著性差异 (P <0 .0 1)。结论 拉米夫定对前 C基因变异慢性乙型肝炎患者肝纤维化有效。
Objective To investigate the effect of lamivudine on fibrosis in chronic hepatitis B patients with pre-C gene mutation. Methods Thirty-nine patients with chronic hepatitis B who were negative for HBeAg and positive for HBV DNA, two or more of the four indicators of serum hepatic fibrosis were randomly divided into lamivudine group (26 cases) and control group Thirteen patients were tested for HBV DNA, TB, ALT, A / G and HA, LN, PC and C before and after treatment. Results Twenty-three of 26 patients in the lamivudine group had negative HBV DNA, the rate of negative conversion was 88.46%, TB, ALT decreased significantly, and A / G increased significantly. There was a significant difference between the two groups (P <0 .0 1 liver fibrosis indicators were significantly decreased, the two groups were significantly different (P <0.01) .Conclusion lamivudine pre-C gene mutation Chronic hepatitis B patients with liver fibrosis effective.